Utility of the nonabsorbed (<0.4%) antibiotic rifaximin in gastroenterology and hepatology

Gastroenterology and Hepatology

Volumn 2, Issue 3, 2006, Pages 186-197

  Su, Chinyu G ^a   Aberra, Faten ^a   Lichtenstein, Gary R ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antibiotic; Minimally absorbed; Rifaximin

Indexed keywords

ANTIBIOTIC AGENT; CHLORTETRACYCLINE; CIPROFLOXACIN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; ETHINYLESTRADIOL; GENTAMICIN; IMMUNOSUPPRESSIVE AGENT; LACTITOL; LACTULOSE; MESALAZINE; MIDAZOLAM; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; RIFAXIMIN; VANCOMYCIN;

ABDOMINAL PAIN; ADD ON THERAPY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL OVERGROWTH; BACTERIUM ISOLATE; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ENTERITIS; FLATULENCE; HEPATIC ENCEPHALOPATHY; HUMAN; ILEITIS; IN VITRO STUDY; INFECTION PREVENTION; INFECTIOUS DIARRHEA; MEDICAL DOCUMENTATION; MEDICAL SPECIALIST; META ANALYSIS; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; POSTOPERATIVE INFECTION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SHIGELLOSIS; SINGLE DRUG DOSE; SMALL INTESTINE; SYSTEMATIC REVIEW; TRAVELLER DIARRHEA; ULCERATIVE COLITIS; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 33846001302     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Gregg CR. Enteric bacterial flora and bacterial overgrowth syndrome. Semin Gastrointest Dis. 2002;13:200-209.
2. Go MF. Treatment and management of Helicobacter pylori infection. Curr Gastroenterol Rep. 2002;4:471-477.
3. Park SI, Giannella RA. Approach to the adult patient with acute diarrhea. Gastroenterol Clin North Am. 1993;22:483-497.
4. Blanc P, Daures JP, Liautard J, et al. Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial. Gastroenterol Clin Biol. 1994;18:1063-1068.
5. Marteau P, Seksik P, Shanahan F. Manipulation of the bacterial flora in inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2003;17:47-61.
6. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412-419.
7. National Center for Health Statistics, GJ Gardocki. Use of antimicrobial drugs in office-based practice, United States, 1980-81. Vital and Health Statistics Series 13, no. 85. Washington, DC: Public Health Service; US Government Printing Office; June 1986. DHHS Pub. No. (PHS) 86-1746.
8. Sharma VK, Vasudeva R, Howden CW. A survey of gastroenterologists; perceptions and practices related to Helicobacter pylori infection. Am J Gastroenterol. 1999;94:3170-3174.
9. Pithie AD, Ellis CJ. Antibiotics and the gut. Aliment Pharmacol Ther. 1989;3:321-332.
10. Lolekha S. Consequences of treatment of gastrointestinal infections. Scand J Infect Dis Suppl. 1986;49:154-159.
11. Levy J. The effects of antibiotic use on gastrointestinal function. Am J Gastroenterol. 2000;95(1 Suppl):S8-S10.
12. DuPont HL. Treatment of travelers' diarrhea. J Travel Med. 2001;8(suppl 2):S31-S33.
13. Steffen R. The emerging role of nonabsorbable oral antibiotic therapy in the management of travelers' diarrhea. Adv Stud Med. 2003;3: S951-S958.
14. DuPont HL. Community-acquired diarrheal disease in western countries: applications of nonabsorbable oral antibiotic therapy. Adv Stud Med. 2003;3:S945-S950.
15. Marchi E, Montecchi L, Venturini AP, et al. 4-Deoxypyrido[1′, 2′:1, 2]imidazo[5,4-c]rifamycin SV derivatives: a new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption. J Med Chem. 1985;28:960-963.
16. Gillis JC, Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs. 1995;49:467-484.
17. Chambers HF. Antimicrobial agents: general considerations. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York: McGraw-Hill; 2001:1143-1170.
18. Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother. 2000;44:2205-2206.
19. Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity-a review. Chemotherapy. 2005;51(suppl 1):67-72.
20. DuPont H, Ericsson CD, Mathewson JJ, et al. Rifaximin: a non-absorbed antimicrobial in the therapy of travelers' diarrhea. Digestion. 1998;59:708-714.
21. Data on file, Salix Pharmaceuticals. Study Report CD0003.07, Nov 12, 2003. This information can be obtained from Salix Pharmaceuticals, Inc. by phoning 1-800-669-7597.
22. Rifaximin New Drug Application. NDA 21-361. Salix Pharmaceuticals, Inc., 2001. This information can be obtained from Salix Pharmaceuticals, Inc. by phoning 1-800-669-7597.
23. Descombe JJ, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res. 1994;14:51-56.
24. Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci. 1999;44:1220-1221.
25. Trapnell CB, Taylor DN, Montgomery C, et al. Systemic pharmacokinetics of rifaximin in subjects with shigellosis. Paper presented at: Annual Meeting of American Society of Clinical Pharmacology and Therapeutics; March 2-5, 2005; Orlando, Fla.
26. Xifaxan (rifaximin) Tablets 200 mg [package insert]. Raleigh, NC: Salix Pharmaceuticals, Inc. 2004.
27. King A, Laurie R, Connolly M, et al. The effect of rifaximin on the pharmacokinetics of single doses of intravenous and oral midazolam in healthy volunteers. [abstract.] Clin Pharmacol Ther. 2004;75:P66.
28. King A, Marshall O, Connolly M. The effect of rifaximin on the pharmacokinetics of a single dose of ethinyl estradiol and norgestimate in healthy female volunteers. Clin Pharmacol Ther. 2004;75:P96.
29. Steffen R, Sack DA, Riopel L, et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastro. 2003;98:1073-1078.
30. DuPont HL, Jiang Z-D, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: A randomized, double-blind clinical trial. Clin Infect Dis. 2001;33:1807-1815.
31. Infante RM, Ericsson CD, Jiang Z-D, et al. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol. 2004;2:135-138.
32. Stornello C, Salanitri G. Controlled trial on the clinical effectiveness of the new antidiarrheal drug rifaximin. Med Praxis. 1987;8:69-78.
33. De Castro R, Domenichelli V, Di Lorenzo FP, et al. Rifaximin treatment for acute recurrent diarrhea in children with genitourinary disorders. Curr Ther Res. 1998;59:746-752.
34. Vinci M, Gatto A, Giglio A, et al. Double-blind clinical trial on infectious diarrhoea therapy: rifaximin versus placebo. Curr Ther Res. 1984;36:92-99.
35. Della Marchina M, Renzi G, Palazzini E. Infectious diarrhea in the aged: controlled clinical trial of rifaximin. Chemoterapia. 1988;7:336-340.
36. Sanfilippo A, Longo GR, Longo AR. Clinical experience with rifaximin in pediatric diarrhoeal syndromes. Med Praxis. 1984;5:375-383.
37. Mazzitelli M, Brega G, Dirani D, et al. Antidiarrhoeal effectiveness and tolerance in man of a local antibiotic: Rifaximin. Comparative assessment using a control drug. Eur Rev Med Pharmacol Sci. 1984;VI:301-306.
38. Palermo G, De Gregorio P, Coffa G. Effectiveness of the L 105 compound in the treatment of acute diarrhoeal diseases: a short-term controlled study. Med Praxis. 1984;5:147-152.
39. Frisari L, Viggiano V, Pelagalli M. An open, controlled study of two non-absorbable antibiotics for the oral treatment of paediatric infectious diarrhoea. Curr Med Res Opin. 1997;14:39-45.
40. Beseghi U, De Angelis GL. Comparison of two non-absorbable antibiotics for treatment of bacterial enteritis in children. Eur Rev Med Pharmacol Sci. 1998;3-4:131-136.
41. Alvisi V, D'Ambrosi A, Onofri W, et al. Treatment of secretory diarrhoeas: a double-blind trial of the effectiveness of rifaximin and neomycin. Clin Trials J. 1984;21:215-222.
42. Fiorentino F, Simioli F, Conte M, et al. Open study on the antidiarrhoeal effectiveness of the L 105 compound. Chemoterapia. 1984;111:132-135.
43. Ambrosioni G, Giovannini G, Lambertini A, et al. Activity and tolerance evaluation in children of a new antidiarrhoeal drug: rifaximin. La Clinica Pediatrica. 1986;66:1-10.
44. Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res. 1993;54:598-609.
45. Puxeddu A, Quartini M, Massimetti A, et al. Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin. 1995;13:274-281.
46. Williams R, James OFW, Warnes TW, et al. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multicentre study. Eur J Gastroenterol Hepatol. 2000;12:203-208.
47. Mas A, Rodés J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;28:51-58.
48. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin. 1993;13:109-118.
49. Massa P, Vallerino E, Dodero M, et al. Treatment of hepatic encephalopathy with rifaximin: double-blind, double-dummy study versus lactulose. Eur J Clin Res. 1993;4:7-18.
50. Giacomo F, Francesco A, Michele N, et al. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res. 1993;4:57-66.
51. Pedretti G, Calzetti C, Missale G, et al. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial. Ital J Gastroenterol. 1991;23:175-178.
52. Di Piazza S, Filippazzo MG, Valenza LM, et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol. 1991;23:403-407.
53. Miglio F, Valpiani D, Rossellini SR, et al. Rifaximin, a nonabsorbable rifamycin, for the treatment of hepatic encephalopathy: a double-blind, randomised trial. Curr Med Res Opin. 1997;13:593-601.
54. Testa R, Eftimiadi C, Sukkar GS, et al. A nonabsorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res. 1985;20:387-392.
55. De Marco F, Amato PS, D'Arienzo A. Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. Curr Ther Res Clin Exp. 1984;36:668-674.
56. Parini P, Cipolla A, Ronchi M, et al. Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res Clin Exp. 1992;52:34-39.
57. Sama C, Morselli-Labati AM, Pianta P, et al. Clinical effects of rifaximin in patients with hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: an open-label pilot study. Curr Ther Res Clin Exp. 2004;65:413-422.
58. Song H, Lee KS, Kim MH, et al. The clinical efficacy of rifaximin in the treatment of hepatic encephalopathy. Hepatology. 2000;32:407A. Abstract 989.
59. Loguercio G, Federico A, De Girolamo V, et al. Cyclic treatment of chronic hepatic encephalopathy with rifaximin: results of a double-blind clinical study. Minerva Gastroenterol Dietol. 2003;49:53-62.
60. Bass NM, Gardner JD, Kamm AR, et al. Rifaximin is beneficial for the treatment of hepatic encephalopathy. Paper presented at: 53rd Annual Meeting of the American Association for the Study of Liver Diseases; Oct 29-Nov 2, 2004; Boston, Mass.
61. Lata J, Hulek P, Kralove H, et al. Safety and efficacy of rifaximin in the treatment of hepatic encephalopathy in liver cirrhosis. [Abstract] Hepatology. 2002;36:519A.
62. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. BMJ. 2004;328:1046.
63. Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:41-62.
64. Guslandi M, Giollo P, Testoni PA. Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic, in active ulcerative colitis: preliminary clinical experience. Curr Ther Res Clin Exp. 2004;65:292-296.
65. Riegler G, Russo MI, Carratu R, et al. Clinical and therapeutic considerations in the treatment of nonspecific abdominal disorders in patients with quiescent ulcerative rectocolitis: preliminary notes on treatment with rifaximine. Eur Rev Med Pharmacol. 1992;14:9-14.
66. Pinto A, Borruto G, Dall'Anna A, et al. An open-uncontrolled trial of oral rifaximin, a non-absorbable antibiotic, in inflammatory bowel disease refractory to conventional therapy. Eur J Clin Res. 1997;9:217-224.
67. Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin. 2005;21:1165-1169.
68. Kornbluth A, Hunt M, George J, et al. Efficacy and safety of rifaximin in the treatment of mild-moderate Crohn's disease: results of an open-label pilot study. Presentation W1029 at: Digestive Diseases Week; May 15-19, 2005; Chicago, Ill.
69. Bosworth BP, Scherl EJ. A novel nonabsorbable antibiotic (rifaximin) in the treatment of moderate-to-severe Crohn's disease. Presentation W1013 at: Digestive Diseases Week; May 15-19, 2005; Chicago, Ill.
70. Biancone L, Ferrieri A, Silvestria M, et al. Rifaximin in inactive Crohn's disease: effect on the intestinal protein loss as assessed by the fecal alpha1-antitrypsin clearance. J Clin Res. 1998;1:289-301.
71. Huang DB, DuPont HL. Rifaximin-a novel antimicrobial for enteric infections. J Infect. 2005;50:97-106.
72. Giochetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999;13:713-718.
73. Baidoo L, Kundu R, Wolf D, et al. Rifaximin is an effective antibiotic for the treatment of pouchitis. Presentation M1975 at: Digestive Diseases Week; May 15-19, 2005; Chicago, Ill.
74. Di Stefano M, Malservisi S, Veneto G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2000;14:551-556.
75. Trespi E, Ferrieri A. Intestinal bacterial overgrowth during chronic pancreatitis. Curr Med Res Opin. 1999;19:47-52.
76. Corazza GR, Ventrucci M, Strocchi A, et al. Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin. J Int Med Res. 1988;16:312-316.
77. Baidoo L, Kundu R, Berenbaum PL, et al. Rifaximin is effective therapy for small bowel bacterial overgrowth. Presentation W1732 at: Digestive Diseases Week; May 15-19, 2005; Chicago, Ill.
78. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292:852-858.
79. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj L. Rifaximin in abdominal bloating and flatulence trial: a randomized, double-blind placebo-controlled trial. Am J Gastroenterol. 2006;101:326-333.
80. Lauritano C, Gabrielli M, Lupascu A, et al. A dose-finding study of rifaximin for the treatment of small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Presentation T1145 at: Digestive Diseases Week; May 15-19, 2005; Chicago, Ill. Available at: http://www.medscape.com/ viewarticle/507463. Accessed March 1, 2006.
81. Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995;16:459-477.
82. Boero M, Berti E, Morgando A, et al. Treatment for colitis caused by Clostridium difficile: results of a randomized open study of rifaximine vs vancomycin. Microbiologia Medica. 1990;5:74-77.
83. Gruttadauria G, La Barbera F, Cutaia G, et al. Prevention of infection in colonic surgery by rifaximin: a controlled, prospective, randomized trial. Eur Rev Med Pharmacol Sci. 1987;9:101-105.
84. Bresadola F, Intini S, Anania G, et al. Chemoprophylaxis in the preparation of the large intestine surgery: oral rifaximin vs intravenous cephalosporin. Ann Ital Chir. 1992;63:201-207.
85. Verardi S, Verardi V, Fusillo M. Rifaximin effectiveness evaluation in the preparation of large intestine to surgery. Eur Rev Med Pharmacol Sci. 1986;8:267-270.
86. Scalco GB, Rossi MR, Rubbini M, et al. Rifaximin: a new rifamycin for the prophylaxis of the septic complications in the large bowel surgery. Policlinico Sez Chir. 1987;94:41-45.
87. Porta E, Berta V. A new prophylaxis program for colorectal surgery. Chir Gastroent. 1992;26:401-408.
88. DuPont HL, Ziang Z-D, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005;142:805-12.
89. Erratum in: Ann Intern Med. 2005;143:239.
90. Taylor DN, McKenzie R, Durbin A, et al. Double-blind, placebo-controlled trial to evaluate the use of rifaximin to prevent diarrhea in subjects challenged with Shigella flexneri. Presented at: 53rd Annual Meeting of the American Society of Tropical Medicine and Hygiene; Nov 7-11, 2004; Miami, Fla.
91. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal gram-negative flora and enterococci. Clin Microbiol Infect. 2004;10:1009-1011.
92. Soro O, Pesce A, Raggi M, et al. Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin Microbiol Infect. 1997;3:147-151.
93. Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord. 2005;5:19-30.
94. Helwig U, Gionchetti P, Rizzello F, et al. CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue. Int J Colorectal Dis. 2004;19:165-170.
95. Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion. 2002;66:246-256.
96. Pimentel M, Park S, Kong Y, et al. Rifaximin, a non-absorbable antibiotic, improves the symptoms of irritable bowel syndrome: a double-blind randomized controlled study. Presented at: 70th Annual Scientific Meeting of the American College of Gastroenterology; Oct 30-Nov 2, 2005, Honolulu, Hawaii.
97. Baidoo L, Blonski W, Kundu R, et al. Rifaximin for mild to moderately active Crohn's disease. Presented at: 70th Annual Scientific Meeting of the American College of Gastroenterology; Oct 30-Nov 2, 2005, Honolulu, Hawaii.
98. Feldman D, Baradarian R, Iswara K, et al. Rifaximin as a steroid-sparing medication in the management of patients with inflammatory bowel disease. Presented at: 70th Annual Scientific Meeting of the American College of Gastroenterology; Oct 30-Nov 2, 2005; Honolulu, Hawaii.